B. Schmidt

Metabolism of lergotrile to 13-hydroxy lergotrile, a potent inhibitor of prolactin release in vitro.

C. Shaar, C. Parli, B. Schmidt, 1978, Biochemical pharmacology.

Subchronic treatment with anxiolytic doses of the 5-HT1A receptor agonist ipsapirone does not affect 5-HT2 receptor sensitivity in the rat.

V. Baudrie, F. Chaouloff, J. de Vry, 1993, European journal of pharmacology.

Changes in anterior pituitary hormone levels after serotonin 1A receptor stimulation.

C. Oliver, M. Bluet-Pajot, F. Mounier, 1990, Endocrinology.

Preparation of 5-bromotetronates [4-alkoxy-5-bromo-2(5H)-furanones] and a new concept for the synthesis of aflatoxins and related structure types. Tributyltin hydride versus palladium-promoted intramolecular hydroarylation.

H. Martin, R. Hoffmann, B. Schmidt, 1989 .

Metabolism of 6-chlorotryptophan to 4-chloro-3-hydroxyanthranilic acid: a potent inhibitor of 3-hydroxyanthranilic acid oxidase.

C. Parli, B. Schmidt, P. Krieter, 1980, Archives of biochemistry and biophysics.

Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.

J. Greuel, H. Heine, F. Mauler, 1998, The Journal of pharmacology and experimental therapeutics.

Radiosynthesis of the adenosine A3 receptor ligand 5-(2-[18F]fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)- 6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY)

W. Wadsak, D. Haeusler, M. Mitterhauser, 2008 .

Differential sites of action of 8OHDPAT, a 5HT1A agonist, on ACTH and PRL secretion in the rat.

F. Mounier, C. Kordon, B. Schmidt, 1995, Neuroendocrinology.